151 related articles for article (PubMed ID: 32609866)
1. FDA Approves 2 Therapies for Treatment of Metastatic Non-Small Cell Lung Cancer.
Wright KM
Oncology (Williston Park); 2020 Jun; 34(6):202. PubMed ID: 32609866
[TBL] [Abstract][Full Text] [Related]
2. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration.
Mountzios G; Remon J; Novello S; Blais N; Califano R; Cufer T; Dingemans AM; Liu SV; Peled N; Pennell NA; Reck M; Rolfo C; Tan D; Vansteenkiste J; West H; Besse B
Ann Oncol; 2019 Nov; 30(11):1686-1688. PubMed ID: 31504132
[No Abstract] [Full Text] [Related]
3. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC.
Kahl KL
Oncology (Williston Park); 2020 Jul; 34(7):254. PubMed ID: 32674209
[TBL] [Abstract][Full Text] [Related]
5. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
6. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
7. FDA Approves Two New Indications and Dosage Form for Pembrolizumab.
DeVito T; Saleh N
Oncology (Williston Park); 2019 May; 33(5):186. PubMed ID: 31095718
[No Abstract] [Full Text] [Related]
8. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
[No Abstract] [Full Text] [Related]
9. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
[No Abstract] [Full Text] [Related]
10. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
11. Baseline corticosteroids reduce activity of PD-L1 blockade.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e515. PubMed ID: 30177497
[No Abstract] [Full Text] [Related]
12. Atezolizumab and Its Many Uses.
Saleh N; Copur MS
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469902
[No Abstract] [Full Text] [Related]
13. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
14. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: High Stromal TGFBI is a Useful Predictive Marker for Nivolumab in Non-small Cell Lung Cancer.
Nakazawa N; Yokobori T; Turtoi A; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):943-944. PubMed ID: 31696394
[No Abstract] [Full Text] [Related]
17. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
[TBL] [Abstract][Full Text] [Related]
18. Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.
Kubo S; Kobayashi N; Somekawa K; Hirata M; Kamimaki C; Aiko H; Katakura S; Teranishi S; Watanabe K; Hara YU; Yamamoto M; Kudo M; Kaneko T
Anticancer Res; 2020 Jul; 40(7):3889-3896. PubMed ID: 32620629
[TBL] [Abstract][Full Text] [Related]
19. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
[TBL] [Abstract][Full Text] [Related]
20. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.
Peters S; Reck M; Smit EF; Mok T; Hellmann MD
Ann Oncol; 2019 Jun; 30(6):884-896. PubMed ID: 30912805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]